Amarin (AMRN) Up as Vascepa Shows Strong Rx Growth Last Week
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin (Nasdaq: AMRN) is indicated higher Thursday following strong weekly prescription numbers.
Bloomberg Industries noted that prescriptions of Vascep for high triglycerides improved 4 percent to 3,401 for the week ended May 24th. By comparison, Glaxo's (NYSE: GSK) Lovaza saw just a 0.5 percent gain in the prior week.
For the four weeks ending May 24, Vascepa prescriptions are up 13.8 percent.
Blocking of channels and/or changes in projection methodology have happened since Vascepa's introduction.
Ahead of the bell, Amarin is up 4 percent.
Bloomberg Industries noted that prescriptions of Vascep for high triglycerides improved 4 percent to 3,401 for the week ended May 24th. By comparison, Glaxo's (NYSE: GSK) Lovaza saw just a 0.5 percent gain in the prior week.
For the four weeks ending May 24, Vascepa prescriptions are up 13.8 percent.
Blocking of channels and/or changes in projection methodology have happened since Vascepa's introduction.
Ahead of the bell, Amarin is up 4 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vaxcyte to release Phase 3 trial data for VAX-31 vaccine candidate
- Evaxion to present EVX-01 cancer vaccine immune data at SITC 2026
- Vera Therapeutics to present ORIGIN 3 trial data at ASN Kidney Week
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
